|
1
|
Forner A, Reig M and Bruix J:
Hepatocellular carcinoma. Lancet. 391:1301–1314. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Yang N, Ekanem NR, Sakyi CA and Ray SD:
Hepatocellular carcinoma and microRNA: New perspectives on
therapeutics and diagnostics. Adv Drug Deliv Rev. 81:62–74. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Bruix J, Gores GJ and Mazzaferro V:
Hepatocellular carcinoma: Clinical frontiers and perspectives. Gut.
63:844–855. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kalluri R and Weinberg RA: The basics of
epithelial-mesenchymal transition. J Clin Invest. 119:1420–1428.
2009. View
Article : Google Scholar : PubMed/NCBI
|
|
5
|
Radisky DC: Epithelial-mesenchymal
transition. J Cell Sci. 118:4325–4326. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wang SH, Wu XC, Zhang MD, Weng MZ, Zhou D
and Quan ZW: Upregulation of H19 indicates a poor prognosis in
gallbladder carcinoma and promotes epithelial-mesenchymal
transition. Am J Cancer Res. 6:15–26. 2015.PubMed/NCBI
|
|
7
|
Huang Q, Han J, Fan J, Duan L, Guo M, Lv
Z, Hu G, Chen L, Wu F, Tao X, et al: IL-17 induces EMT via Stat3 in
lung adenocarcinoma. Am J Cancer Res. 6:440–451. 2016.PubMed/NCBI
|
|
8
|
Li M, Zhang B, Sun B, Wang X, Ban X, Sun
T, Liu Z and Zhao X: A novel function for vimentin: The potential
biomarker for predicting melanoma hematogenous metastasis. J Exp
Clin Cancer Res. 29:1092010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Han J, Wang F, Lan Y, Wang J, Nie C, Liang
Y, Song R, Zheng T, Pan S, Pei T, et al: KIFC1 regulated by
miR-532-3p promotes epithelial-to-mesenchymal transition and
metastasis of hepatocellular carcinoma via gankyrin/AKT signaling.
Oncogene. 38:406–420. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yang X, Zhang XF, Lu X, Jia HL, Liang L,
Dong QZ, Ye QH and Qin LX: MicroRNA-26a suppresses angiogenesis in
human hepatocellular carcinoma by targeting hepatocyte growth
factor-cMet pathway. Hepatology. 59:1874–1885. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Liu Y, Qiao Y, Hu C, Liu L, Zhou L, Liu B,
Chen H and Jiang X: VEGFR2 inhibition by RNA interference affects
cell proliferation, migration, invasion, and response to radiation
in Calu-1 cells. Clin Transl Oncol. 18:212–219. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Minata M, Harada KH, Kudo M, Ikai I and
Nishida N: The prognostic value of vascular endothelial growth
factor in hepatocellular carcinoma for predicting metastasis after
curative resection. Oncology. 84 (Suppl 1):75–81. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Chatterjee S, Heukamp LC, Siobal M,
Schöttle J, Wieczorek C, Peifer M, Frasca D, Koker M, König K,
Meder L, et al: Tumor VEGF:VEGFR2 autocrine feed-forward loop
triggers angiogenesis in lung cancer. J Clin Invest. 123:1732–1740.
2013. View
Article : Google Scholar : PubMed/NCBI
|
|
14
|
Tian S, Quan H, Xie C, Guo H, Lü F, Xu Y,
Li J and Lou L: YN968D1 is a novel and selective inhibitor of
vascular endothelial growth factor receptor-2 tyrosine kinase with
potent activity in vitro and in vivo. Cancer Sci. 102:1374–1380.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Li F, Liao Z, Zhao J, Zhao G, Li X, Du X,
Yang Y and Yang J: Efficacy and safety of Apatinib in stage IV
sarcomas: Experience of a major sarcoma center in China.
Oncotarget. 8:64471–64480. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Li J, Qin S, Xu J, Xiong J, Wu C, Bai Y,
Liu W, Tong J, Liu Y, Xu R, et al: Randomized, double-blind,
placebo-controlled phase III trial of apatinib in patients with
chemotherapy-refractory advanced or metastatic adenocarcinoma of
the stomach or gastroesophageal junction. J Clin Oncol.
34:1448–1454. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Hu X, Zhang J, Xu B, Jiang Z, Ragaz J,
Tong Z, Zhang Q, Wang X, Feng J, Pang D, et al: Multicenter phase
II study of apatinib, a novel VEGFR inhibitor in heavily pretreated
patients with metastatic triple-negative breast cancer. Int J
Cancer. 135:1961–1969. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Li J, Qin S, Xu J, Guo W, Xiong J, Bai Y,
Sun G, Yang Y, Wang L, Xu N, et al: Apatinib for
chemotherapy-refractory advanced metastatic gastric cancer: Results
from a randomized, placebo-controlled, parallel-arm, phase II
trial. J Clin Oncol. 31:3219–3225. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Qin S, Bai Y, Ouyang X, Cheng Y, Li J, Xu
J, Liang J, Li Q, Wu W and Liu W: Apatinib for patients with
advanced hepatocellular carcinoma: A randomised, open-label,
multicentre, phase II clinical trial. Lin Chuang Zhong Liu Xue Za
Zhi. 22:1057–1065. 2017.(In Chinese).
|
|
20
|
Liu S, Su L, Mu X, Shi Y, Zhang A and Ge
X: Apatinib inhibits macrophage-mediated epithelial - mesenchymal
transition in lung cancer. RSC Advances. 8:21451–21459. 2018.
View Article : Google Scholar
|
|
21
|
Chen Y, Chen X, Ding X and Wang Y:
Afatinib, an EGFR inhibitor, decreases EMT and tumorigenesis of Huh
7 cells by regulating the ERK VEGF/MMP9 signaling pathway. Mol Med
Rep. 20:3317–3325. 2019.PubMed/NCBI
|
|
22
|
Zhang Y, Wang SJ, Han ZH, Li YQ, Xue JH,
Gao DF, Wu XS and Wang CX: PI3K/AKT signaling pathway plays a role
in enhancement of eNOS activity by recombinant human angiotensin
converting enzyme 2 in human umbilical vein endothelial cells. Int
J Clin Exp Pathol. 7:8112–8117. 2014.PubMed/NCBI
|
|
23
|
Xu W, Yang Z and Lu N: A new role for the
PI3K/Akt signaling pathway in the epithelial-mesenchymal
transition. Cell Adhes Migr. 9:317–324. 2015. View Article : Google Scholar
|
|
24
|
Yu X, Zheng Y, Zhu X, Gao X, Wang C, Sheng
Y, Cheng W, Qin L, Ren N, Jia H, et al: Osteopontin promotes
hepatocellular carcinoma progression via the PI3K/AKT/Twist
signaling pathway. Oncol Lett. 16:5299–5308. 2018.PubMed/NCBI
|
|
25
|
Scott AJ, Messersmith WA and Jimeno A:
Apatinib: A promising oral antiangiogenic agent in the treatment of
multiple solid tumors. Drugs Today (Barc). 51:223–229. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Liu K, Ren T, Huang Y, Sun K, Bao X, Wang
S, Zheng B and Guo W: Apatinib promotes autophagy and apoptosis
through VEGFR2/STAT3/BCL-2 signaling in osteosarcoma. Cell Death
Dis. 8:e30152017. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zheng B, Ren T, Huang Y and Guo W:
Apatinib inhibits migration and invasion as well as PD-L1
expression in osteosarcoma by targeting STAT3. Biochem Biophys Res
Commun. 495:1695–1701. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Huang M, Huang B, Li G and Zeng S:
Apatinib affect VEGF-mediated cell proliferation, migration,
invasion via blocking VEGFR2/RAF/MEK/ERK and PI3K/AKT pathways in
cholangiocarcinoma cell. BMC Gastroenterol. 18:1692018. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Saxena NK, Sharma D, Ding X, Lin S, Marra
F, Merlin D and Anania FA: Concomitant activation of the JAK/STAT,
PI3K/AKT, and ERK signaling is involved in leptin-mediated
promotion of invasion and migration of hepatocellular carcinoma
cells. Cancer Res. 67:2497–2507. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zhou Q, Lui VW and Yeo W: Targeting the
PI3K/Akt/mTOR pathway in hepatocellular carcinoma. Future Oncol.
7:1149–1167. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Fathi Maroufi N, Rashidi MR, Vahedian V,
Akbarzadeh M, Fattahi A and Nouri M: Therapeutic potentials of
Apatinib in cancer treatment: Possible mechanisms and clinical
relevance. Life Sci. 241:1171062020. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Lou L, Ye W, Chen Y, Wu S, Jin L, He J,
Tao X, Zhu J, Chen X, Deng A, et al: Ardipusilloside inhibits
survival, invasion and metastasis of human hepatocellular carcinoma
cells. Phytomedicine. 19:603–608. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Liao X, Tao L, Guo W, Wu ZX, Du H, Wang J,
Zhang J, Chen H, Chen ZS, Lin L, et al: Combination of Cordycepin
and Apatinib Synergistically Inhibits NSCLC Cells by
Down-Regulating VEGF/PI3K/Akt Signaling Pathway. Front Oncol.
10:17322020. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Chen T, You Y, Jiang H and Wang ZZ:
Epithelial-mesenchymal transition (EMT): A biological process in
the development, stem cell differentiation, and tumorigenesis. J
Cell Physiol. 232:3261–3272. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Song L, Li XX, Liu XY, Wang Z, Yu Y, Shi
M, Jiang B and He XP: EFEMP2 suppresses the invasion of lung cancer
cells by inhibiting epithelial-mesenchymal transition (EMT) and
down-regulating MMPs. OncoTargets Ther. 13:1375–1396. 2020.
View Article : Google Scholar
|
|
36
|
Piao HL, Yuan Y, Wang M, Sun Y, Liang H
and Ma L: α-catenin acts as a tumour suppressor in
E-cadherin-negative basal-like breast cancer by inhibiting NF-κB
signalling. Nat Cell Biol. 16:245–254. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Niknami Z, Eslamifar A, Emamirazavi A,
Ebrahimi A and Shirkoohi R: The association of vimentin and
fibronectin gene expression with epithelial-mesenchymal transition
and tumor malignancy in colorectal carcinoma. EXCLI J.
16:1009–1017. 2017.PubMed/NCBI
|
|
38
|
Yamaguchi R, Yano H, Nakashima Y,
Ogasawara S, Higaki K, Akiba J, Hicklin DJ and Kojiro M: Expression
and localization of vascular endothelial growth factor receptors in
human hepatocellular carcinoma and non-HCC tissues. Oncol Rep.
7:725–729. 2000.PubMed/NCBI
|
|
39
|
Chen H, Shen YF, Gong F, Yang GH, Jiang YQ
and Zhang R: Expression of VEGF and its effect on cell
proliferation in patients with chronic myeloid leukemia. Eur Rev
Med Pharmacol Sci. 19:3569–3573. 2015.PubMed/NCBI
|
|
40
|
Podar K and Anderson KC: Inhibition of
VEGF signaling pathways in multiple myeloma and other malignancies.
Cell Cycle. 6:538–542. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Lin D and Wu J: Hypoxia inducible factor
in hepatocellular carcinoma: A therapeutic target. World J
Gastroenterol. 21:12171–12178. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Song P, Gao J, Inagaki Y, Kokudo N,
Hasegawa K, Sugawara Y and Tang W: Biomarkers: Evaluation of
screening for and early diagnosis of hepatocellular carcinoma in
Japan and China. Liver Cancer. 2:31–39. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Buijs N, Oosterink JE, Jessup M,
Schierbeek H, Stolz DB, Houdijk AP, Geller DA and van Leeuwen PA: A
new key player in VEGF-dependent angiogenesis in human
hepatocellular carcinoma: Dimethylarginine dimethylaminohydrolase
1. Angiogenesis. 20:557–565. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Bhoori S and Mazzaferro V: Combined
immunotherapy and VEGF-antagonist in hepatocellular carcinoma: A
step forward. Lancet Oncol. 21:740–741. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Yao Y, Wang T, Liu Y and Zhang N:
Co-delivery of sorafenib and VEGF-siRNA via pH-sensitive liposomes
for the synergistic treatment of hepatocellular carcinoma. Artif
Cells Nanomed Biotechnol. 47:1374–1383. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Yang C and Qin S: Apatinib targets both
tumor and endothelial cells in hepatocellular carcinoma. Cancer
Med. 7:4570–4583. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Shen K, Ji L, Gong C, Ma Y, Yang L, Fan Y,
Hou M and Wang Z: Notoginsenoside Ft1 promotes angiogenesis via
HIF-1α mediated VEGF secretion and the regulation of PI3K/AKT and
Raf/MEK/ERK signaling pathways. Biochem Pharmacol. 84:784–792.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Jin Z, Cheng X, Feng H, Kuang J, Yang W,
Peng C, Shen B and Qiu W: Apatinib inhibits angiogenesis via
suppressing Akt/GSK3β/ANG signaling pathway in anaplastic thyroid
cancer. Cell Physiol Biochem. 44:1471–1484. 2017. View Article : Google Scholar : PubMed/NCBI
|
